Aurinia Pharmaceuticals Inc.
http://www.auriniapharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Aurinia Pharmaceuticals Inc.
AI/ML Efficiency Gains Could Add Billions To Drug Revenues, Report Finds
A report from Accenture, based on interviews with 75 R&D execs from large biopharma companies, found adopting the technology could cut costs by up to 45%.
Flagship Plans To Distribute New Fund To About Two Dozen Companies
The venture capital firm announced a $3.6bn raise for Fund VIII and side funds, which it plans to invest across human health, AI and sustainability-focused companies.
US Rejected Drug Odronextamab Among 11 EU Marketing Hopefuls
Regeneron, whose blood cancer treatment odronextamab was recently turned down by the US regulator but not for reasons relating to efficacy or safety, could soon learn whether its product will be among the drugs to get the thumbs up from the CHMP, the European Medicines Agency’s human medicines committee.
Stock Watch: Why Have All The Buyouts Gone?
Clinical trial results that readily excite stock market investors are subject to more stringent analysis by big pharma deal-hunters, despite their urgent need for pipeline renewal.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Alberta Ltd.
- Isotechnika Pharma Inc.
- Thunderbolt Pharma, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice